Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV)

Plant Cell Reports

Volumn 31, Issue 3, 2012, Pages 495-511

  Rosales Mendoza, Sergio ^a   Rubio Infante, Néstor ^a   Govea Alonso, Dania O ^a   Moreno Fierros, Leticia ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

HIV prevention; HIV vaccines; Oral immunization; Plant based vaccines; Transgenic plants

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PLANT; REVIEW; TRANSGENIC PLANT;

AIDS VACCINES; ANTIGENS, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, GAG; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PLANTS; PLANTS, GENETICALLY MODIFIED; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84856954023     PISSN: 07217714     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00299-011-1194-8     Document Type: Review

References (101)

1. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
2. Ali Z, Schumacher HM, Heine-Dobbernack E, El-Banna A, Hafeez FY, Jacobsen HJ, Kiesecker H (2010) Dicistronic binary vector system-A versatile tool for gene expression studies in cell cultures and plants. J Biotechnol 145: 9-16.
3. Arulanandam BP, O'Toole M, Metzger DW (1999) Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 180: 940-994.
4. Barbante A, Irons S, Hawes C, Frigerio L, Vitale A, Pedrazzini E (2008) Anchorage to the cytosolic face of the endoplasmic reticulum membrane: a new strategy to stabilize a cytosolic recombinant antigen in plants. Plant Biotechnol J 6: 560-575.
5. Barouch DH, Korber B (2010) HIV-1 vaccine development after STEP. Annu Rev Med 61: 153-167.
6. Benson EM, Clarkson J, Law M, Marshall P, Kelleher AD, Smith DE, Patou G, Stewart GJ, Cooper DA, French RA (1999) Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 15: 105-113.
7. Burke B, Barnett SW (2007) Broadening our view of protective antibody responses against HIV. Curr HIV Res 5: 625-641.
8. Burkinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubei A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M (1993) A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365: 666-669.
9. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Buttò S, Heeney J, Verani P, Titti F, Ensoli B (1999) Control of SHIV-89. 6-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 6: 643-650.
10. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J (1991) Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 302: 23-26.
11. Cueno ME, Hibi Y, Imai K, Laurena AC, Okamoto T (2010a) Impaired plant growth and development caused by human immunodeficiency virus type 1 Tat. Transgenic Res 19: 903-913.
12. Cueno ME, Hibi Y, Karamatsu K, Yasutomi Y, Imai K, Laurena AC, Okamoto T (2010b) Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant. Transgenic Res 19: 889-895.
13. Daniell H (2006) Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. Biotechnol J 1: 1071-1079.
14. de Virgilio M, De Marchis F, Bellucci M, Mainieri D, Rossi M, Benvenuto E, Arcioni S, Vitale A (2008) The human immunodeficiency virus antigen Nef forms protein bodies in leaves of transgenic tobacco when fused to zeolin. J Exp Bot 59: 2815-2829.
15. Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, Blumenthal R (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46: 1398-1401.
16. Doms R (2004) Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Top HIV Med 12: 100-103.
17. Durrani Z, McInerney TL, McLain L, Jones T, Bellaby T, Brennan FR, Dimmock NJ (1998) Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 220: 93-103.
18. Dyer WB, Kuipers H, Coolen MW, Geczy AF, Forrester J, Workman C, Sullivan JS (2002) Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets. AIDS Res Hum Retroviruses 18: 999-1010.
19. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E (2010) Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE 5: e13540.
20. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
21. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B (2008) A fusion intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 105: 3739-3744.
22. Gamble LJ, Matthews QL (2010) Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 22: 9-26.
23. Girard MP, Osmanov SK, Kieny MP (2006) A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24: 4062-4081.
24. Goldstein G (1996) HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2: 960-964.
25. Goldstein G, Manson K, Tribbick G, Smith R (2000) Minimization of chronic plasmazviremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 25: 2789-2795.
26. Gonzalez-Rabade N, McGowan EG, Zhou F, McCabe MS, Bock R, Dix PJ, Gray JC, Ma JK (2011) Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice. Plant Biotechnol J 9: 629-638.
27. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, Starling AK, Traore F, Sall F, Wong KG, Cherne SL, Anderson DJ, Dye SA, Smith RA, Mullins JI, Kiviat NB, Sow PS, University of Washington-Dakar HIV-2 Study Group (2009) Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 48: 476-483.
28. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF (2010) Immunization with cocktail of HIV-derived peptides in Montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 5: e11995.
29. Greco R, Michel M, Guetard D, Cervantes-Gonzalez M, Pelucchi N, Wain-Hobson S, Sala F, Sala M (2007) Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. Vaccine 25: 8228-8240.
30. Guerrero GG, Moreno-Fierros L (2007) Carrier potential properties of Bacillus thuringiensis Cry1A toxins for a diphtheria toxin epitope. Scand J Immunol 66: 610-618.
31. Gupta S, Boppana R, Mishra GC, Saha B, Mitra D (2008) Interleukin-12 is necessary for the priming of CD4 + T cells required during the elicitation of HIV-1 gp120-specific cytotoxic T-lymphocyte function. Immunology 124: 553-561.
32. Gutiérrez-Ortega A, Avila-Moreno F, Saucedo-Arias LJ, Sánchez-Torres C, Gómez-Lim MA (2004) Expression of a single-chain human interleukin-12 gene in transgenic tobacco plants and functional studies. Biotechnol Bioeng 85: 734-740.
33. Gutiérrez-Ortega A, Sandoval-Montes C, de Olivera-Flores TJ, Santos-Argumedo L, Gómez-Lim MA (2005) Expression of functional interleukin-12 from mouse in transgenic tomato plants. Transgenic Res 14: 877-885.
34. Haynes BF, Ma B, Montefiori DC, Wrin T, Petropoulos CJ, Sutherland LL, Scearce RM, Denton C, Xia SM, Korber BT, Liao HX (2006) Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1primary isolates. Virology 345: 44-55.
35. Herbein G, Gras G, Khan KA, Abbas W (2010) Macrophage signaling in HIV-1 infection. Retrovirology 7: 34.
36. Hladik F, Hope TJ (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6: 20-28.
37. Hone DM, Wu S, Powell RJ, Pascual DW, van Cott J, McGhee J, Fouts TR, Tuskan RG, Lewis GK (1996) Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol 44: 203-207.
38. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J (1998) Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 66: 514-520.
39. Karasev AV, Foulke S, Wellens C, Rich A, Shon KJ, Zwierzynski I, Hone D, Koprowski H, Reitz M (2005) Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 7: 1875-1880.
40. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
41. Kessler M, Mathews MB (1992) Premature termination and processing of human immunodeficiency virus type 1-promoted transcripts. J Virol 66: 4488-4496.
42. Kim TG, Gruber A, Langridge WH (2004) HIV-1 gp120 V3 cholera toxin B subunit fusion gene expression in transgenic potato. Protein Expr Purif 37: 196-202.
43. Klasse PJ, Sanders RW, Cerutti A, Moore JP (2011) How can HIV-Type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. doi: 10. 1089/aid. 2011. 0053.
44. Klein KC, Reed JC, Lingappa JR (2007) Intracellular destinies: degradation, targeting assembly, and endocytosis of HIV Gag. AIDS Rev 9: 150-161.
45. Lamm ME (1997) Interactions of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51: 311-340.
46. Levine MM (2000) Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31: 336-355.
47. Li L, Li HS, Pauza CD, Bukrinsky M, Zhao RY (2005) Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res 15: 923-934.
48. Licciardi PV, Underwood JR (2011) Plant-derived medicines: a novel class of immunological adjuvants. Int Immunopharmacol 11: 390-398.
49. Lindh I, Kalbina I, Thulin S, Scherbak N, Sävenstrand H, Bråve A, Hinkula J, Strid A, Andersson S (2008) Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses. APMIS 116: 985-994.
50. Liu C, Towler MJ, Medrano G, Cramer CL, Weathers PJ (2009) Production of mouse interleukin-12 is greater in tobacco hairy roots grown in a mist reactor than in an airlift reactor. Biotechnol Bioeng 102: 1074-1086.
51. Luftig MA, Mattu M, Di GP, Geleziunas R, Hrin R, Barbato G, Bianchi E, Miller MD, Pessi A, Carfi A (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13: 740-747.
52. Lundquist CA, Tobiume M, Zhou J, Unutmaz D, Aiken C (2002) Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 76: 4625-4633.
53. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Buttò S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, Cafaro A, Ensoli B (2004) Long-term protection against SHIV89. 6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22: 3258-3269.
54. Mallon PW (2007) Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev 9: 3-15.
55. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, Benvenuto E, Capone I (2001) Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 75: 8434-8439.
56. Marusic C, Nuttall J, Buriani G, Lico C, Lombardi R, Baschieri S, Benvenuto E, Frigerio L (2007) Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells. BMC Biotechnol 7: 12.
57. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
58. Matoba N, Magérus A, Geyer BC, Zhang Y, Muralidharan M, Alfsen A, Arntzen CJ, Bomsel M, Mor TS (2004) A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 14: 13584-13589.
59. Matoba N, Kajiura H, Cherni I, Doran JD, Bomsel M, Fujiyama K, Mor TS (2009) Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol J 7: 129-145.
60. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ (1996) Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 14: 799-810.
61. Meyers A, Chakauya E, Shephard E, Tanzer FL, Maclean J, Lynch A, Williamson AL, Rybicki EP (2008) Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol 8: 53.
62. Montroni M, Silvestri G, Butini L, Bartocci C, Regnery C, Danieli G (1992) p24 antigenaemia as a predictor of good immunological responsiveness to zidovudine therapy in asymptomatic HIV infection. AIDS 6: 338-339.
63. Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M (2003) Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 77: 882-890.
64. Obregon P, Chargelegue D, Drake PM, Prada A, Nuttall J, Frigerio L, Ma JK (2006) HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production. Plant Biotechnol J 4: 195-207.
65. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
66. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
67. Pejchal R, Wilson IA (2010) Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des 16: 3744-3753.
68. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
69. Ramírez YJ, Tasciotti E, Gutierrez-Ortega A, Donayre Torres AJ, Olivera-Flores MT, Giacca M, Gómez-Lim MA (2007) Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice. Clin Vaccine Immunol 14: 685-692.
70. Reddy MM, Winger EE, Hargrove D, McHugh T, McKinley GF, Grieco MH (1992) An improved method for monitoring efficacy of anti-retroviral therapy in HIV-infected individuals: a highly sensitive HIV p24 antigen assay. J Clin Lab Anal 6: 125-129.
71. Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP (2010) High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J 8: 38-46.
72. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
73. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
74. Robey FA, Robert-Guroff M (2001) A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells. AIDS Res Hum Retroviruses 17: 533-541.
75. Robey FA, Kelson-Harris T, Roller PP, Robert-Guroff M (1995) A helical epitope in the C4 domain of HIV glycoprotein 120. J Biol Chem 270: 23918-23921.
76. Rolland M, Frahm N, Nickle DC, Jojic N, Deng W, Allen TM, Brander C, Heckerman DE, Mullins JI (2011) Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. PLoS One 6: e17969.
77. Rosales-Mendoza S, Alpuche-Solís AG, Soria-Guerra RE, Moreno-Fierros L, Martínez-González L, Herrera-Díaz A, Korban SS (2009) Expression of an Escherichia coli antigenic fusion protein comprising the heat labile toxin B subunit and the heat stable toxin, and its assembly as a functional oligomer in transplastomic tobacco plants. Plant J 57: 45-54.
78. Sánchez-Hernández C, Gutiérrez-Ortega A, Aguilar-León D, Hernández-Pando R, Gómez-Lim M, Gómez-García B (2010) In vivo activity of plant-based interleukin-12 in the lung of Balb/c mouse. BMC Res Notes 3: 151.
79. Scotti N, Alagna F, Ferraiolo E, Formisano G, Sannino L, Buonaguro L, De Stradis A, Vitale A, Monti L, Grillo S, Buonaguro FM, Cardi T (2009) High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 229: 1109-1122.
80. Shchelkunov SN, Salyaev RK, Pozdnyakov SG, Rekoslavskaya NI, Nesterov AE, Ryzhova TS, Sumtsova VM, Pakova NV, Mishutina UO, Kopytina TV, Hammond RW (2006) Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol Lett 28: 959-967.
81. Shen YJ, Shephard E, Douglass N, Johnston N, Adams C, Williamson C, Williamson AL (2011) A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virol J 8: 265.
82. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC (2009) Human immunodeficiency virus tipe 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algoritm. J Virol 83: 7337-7348.
83. Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S (2011) Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep 30: 1367-1382.
84. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
85. Stevens R, Howard KE, Nordone S, Burkhard M, Dean GA (2004) Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J Virol 78: 8210-8218.
86. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, Reynes JM, Lopalco L, Bomsel M (2009) HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2: 412-426.
87. Varona-Santos JT, Vazquez-Padrón RI, Moreno-Fierros L (2006) Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants. Viral Immunol 19: 237-249.
88. Vázquez RI, Moreno-Fierros L, Neri-Bazán L, De La Riva GA, López-Revilla R (1999) Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. Scand J Immunol 49: 578-584.
89. Villinger F, Ansari AA (2010) Role of IL-12 in HIV infection and vaccine. Eur Cytokine Netw 21: 215-218.
90. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-19.
91. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Principal Investigators PG, Koff WC, Wilson IA, Burton DR, Poignard P (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
92. Webster DE, Thomas MC, Pickering R, Whyte A, Dry IB, Gorry PR, Wesselingh SL (2005) Is there a role for plant-made vaccines in the prevention of HIV/AIDS? Immunol Cell Biol 83: 239-247.
93. Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, Rosati M, Weiner DB, Felber BK, Pavlakis GN, Sidhu MK, Eldridge JH, Egan MA (2008) Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 26: 4819-4829.
94. Yang OO, Nguyen PT, Kalams SA, Dorfman T, Gottlinger HG, Stewart S, Chen IS, Threlkeld S, Walker BD (2002) Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 76: 1626-1631.
95. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper DC, Koprowski H (1997) Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci USA 94: 5784-5788.
96. Yusibov V, Streatfield SJ, Kushnir N (2011) Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies, and beyond. Hum Vaccin 7: 313-321.
97. Zhang G, Leung C, Murdin L, Rovinski B, White KA (2000) In planta expression of HIV-1 p24 protein using an RNA plant virus-based expression vector. Mol Biotechnol 14: 99-107.
98. Zhang GG, Rodrigues L, Rovinski B, White KA (2002) Production of HIV-1 p24 protein in transgenic tobacco plants. Mol Biotechnol 20: 131-136.
99. Zhou Q, Sharp PA (1995) Novel mechanism and factor for regulation by HIV-1 Tat. EMBO J 14: 321-328.
100. Zhou F, Badillo-Corona JA, Karcher D, Gonzalez-Rabade N, Piepenburg K, Borchers AM, Maloney AP, Kavanagh TA, Gray JC, Bock R (2008) High-level expression of human immunodeficiency virus antigens from the tobacco and tomato plastid genomes. Plant Biotechnol J 6: 897-913.
101. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev 4: 199-210.